These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 25519996)

  • 1. [Cytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases: results of a first feasibility and case control study].
    Heidenreich A; Pfister D; Brehmer B; Porres D
    Urologe A; 2015 Jan; 54(1):14-21. PubMed ID: 25519996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
    Heidenreich A; Pfister D; Porres D
    J Urol; 2015 Mar; 193(3):832-8. PubMed ID: 25254935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
    Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
    Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up.
    Gandaglia G; Fossati N; Stabile A; Bandini M; Rigatti P; Montorsi F; Briganti A
    Eur Urol; 2017 Aug; 72(2):289-292. PubMed ID: 27574820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy].
    Heidenreich A; Ohlmann C; Ozgür E; Engelmann U
    Urologe A; 2006 Apr; 45(4):474-81. PubMed ID: 16465521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study.
    Steuber T; Berg KD; Røder MA; Brasso K; Iversen P; Huland H; Tiebel A; Schlomm T; Haese A; Salomon G; Budäus L; Tilki D; Heinzer H; Graefen M; Mandel P
    Eur Urol Focus; 2017 Dec; 3(6):646-649. PubMed ID: 28753877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive and Palliative Radical Prostatectomy, Extended Lymphadenectomy and Bilateral Orchiectomy in Advanced Prostate Cancer with Oligo and Widespread Bone Metastases: Result of a Feasibility, Our Initial Experience.
    Simforoosh N; Dadpour M; Mofid B
    Urol J; 2019 May; 16(2):162-167. PubMed ID: 30393838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases?
    Jang WS; Kim MS; Jeong WS; Chang KD; Cho KS; Ham WS; Rha KH; Hong SJ; Choi YD
    BJU Int; 2018 Feb; 121(2):225-231. PubMed ID: 28834084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results.
    Abbas F; Kaplan M; Soloway MS
    Br J Urol; 1996 Mar; 77(3):423-8. PubMed ID: 8814850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laparoscopic Radical Prostatectomy Plus Extended Lymph Node Dissection in Combination With Immediate Androgen Deprivation Therapy for Cases of pT3-4N0-1M0 Prostate Cancer: A Multimodal Study of 8 Years' Follow-up.
    Yang Y; Luo Y; Hou GL; Huang QX; Pang J; Gao X
    Clin Genitourin Cancer; 2016 Aug; 14(4):e321-7. PubMed ID: 26691668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study.
    Rajwa P; Robesti D; Chaloupka M; Zattoni F; Giesen A; Huebner NA; Krzywon A; Miszczyk M; Moll M; Stando R; Cisero E; Semko S; Checcucci E; Devos G; Apfelbeck M; Gatti C; Marra G; van den Bergh RCN; Goldner G; Rasul S; Ceci F; Dal Moro F; Porpiglia F; Gontero P; Bjartell A; Stief C; Heidenreich A; Joniau S; Briganti A; Shariat SF; Gandaglia G;
    Eur Urol Oncol; 2024 Aug; 7(4):721-734. PubMed ID: 37845121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
    Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective lymph node dissection for castration-resistant prostate cancer.
    Busch J; Hinz S; Kempkensteffen C; Erber B; Klopf C; Weikert S; Miller K; Magheli A
    Urol Int; 2012; 88(4):441-6. PubMed ID: 22398510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robotic radical prostatectomy as the initial step in multimodal therapy for men with high-risk localised prostate cancer: initial experience of 160 men.
    Connolly SS; Cathcart PJ; Gilmore P; Kerger M; Crowe H; Peters JS; Murphy DG; Costello AJ
    BJU Int; 2012 Mar; 109(5):752-9. PubMed ID: 21992472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncological and peri-surgical outcomes of radical prostatectomy for non-metastatic prostate cancer with prostate-specific antigen level of 50 ng/ml or greater.
    Makino K; Nakagawa T; Ito E; Kasahara I; Murata T; Fujimura T; Fukuhara H; Homma Y
    Jpn J Clin Oncol; 2018 May; 48(5):485-490. PubMed ID: 29635526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
    Song C; Kim YS; Hong JH; Kim CS; Ahn H
    BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial.
    Dai B; Zhang S; Wan FN; Wang HK; Zhang JY; Wang QF; Kong YY; Ma XJ; Mo M; Zhu Y; Qin XJ; Lin GW; Ye DW
    Eur Urol Oncol; 2022 Oct; 5(5):519-525. PubMed ID: 35780048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review.
    Becker JA; Berg KD; Røder MA; Brasso K; Iversen P
    Scand J Urol; 2018 Feb; 52(1):1-7. PubMed ID: 28818014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
    Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
    Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.